U.S. Markets closed

Allergan price target lowered to $116 from $132 at Susquehanna

Susquehanna lowered its price target on Allergan to reflect the valuation change due to its DARPin disappointment. The firm noted the company's solid Q1 results but believes the value of DARPin has been diminished making the risk/reward for the drug balanced at best. Shares remain Positive rated.